default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Myongji Hospital, ATGen Group to co-develop immune cell therapy

Lee Han-soo  Published 2018.12.20  14:41  Updated 2018.12.20 14:41

공유
default_news_ad2

Myongji Hospital said Thursday that it signed an open innovation agreement with ATGen Group to jointly develop the next generation anticancer immune cell therapy and conduct technology exchanges.

Myongji Hospital Chairman Lee Wang-jun (third from left in front row) and ATGen Group CEO Park Sang-woo (at Lee’s left) pose for photographers after signing the open innovation agreement at the hospital’s New Horizon Healing Center in Goyang, Gyeonggi Province, on Wednesday.

Under this agreement, Myongji Hospital and ATGen Group will promote the development of the medical industry and technology, by conducting research and development of anti-cancer immunotherapeutic drugs.

The agreement includes joint R&D, technology exchange, joint use of equipment and facilities, exchange of R&D personnel, holding international conferences and seminars, and conducting joint clinical trials.

“The cooperation with a new bio company, which has a basis in hospital platform, has allowed the realization of the goal of the Myongji New Horizon Cancer Research Institute -- open innovation,” Myongji Hospital Chairman Lee Wang-jun said. “Through this agreement, we hope to create synergies in building a new-horizon ecosystem that harmonizes both the medical and biotechnology sectors.”

ATGen Group CEO Park Sang-woo agreed, saying, “Collaboration between ATGen Group, which has its development technology, and Myongji Hospital, which has clinical know-how and research infrastructure, will accelerate the development of excellent treatments.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch